A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines - PubMed (original) (raw)
Affiliations
- PMID: 9139377
Clinical Trial
A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines
S Nimmannitya et al. Southeast Asian J Trop Med Public Health. 1995 Dec.
Erratum in
- Southeast Asian J Trop Med Public Health 1996 Mar;27(1):206
Abstract
A field study to compare the immune response of children aged 1-6 years to Nakayama and Beijing strains JE vaccines was carried out in Mae Hong Son Province, northwest Thailand, where there was low incidence of JEV infection. The first and second dose of each vaccine was given 1-2 weeks apart and the third dose was 1 year after the second dose. Seroconversion rate was similarly high, about 94% in both groups of vaccinees. At 6 and 12 months after 2 doses of vaccines, the seroconversion rates dropped in both groups of vaccinees, so there were 10-20% of children (50-65% if cross protection was considered) susceptible to JEV infections during this period. After the third dose of vaccine, the seroconversion rate rose to 100% in both groups. The GMT in Bejing strain vaccinees were slightly higher than Nakayama strain JE vaccines. To reduce the number of susceptible children during 6-12 months after the second dose and for longer protection, the primary JE immunization should be 3 doses and the timing for the third dose should be at 6 months after the second dose. Either Nakayama or Beijing strain vaccine could be used in Thailand.
Similar articles
- Neutralizing antibody responses to Japanese encephalitis vaccine in children.
Juang RF, Okuno Y, Fukunaga T, Tadano M, Fukai K, Baba K, Tsuda N, Yamada A, Yabuuchi H. Juang RF, et al. Biken J. 1983 Mar;26(1):25-34. Biken J. 1983. PMID: 6626137 - Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P. Monath TP, et al. J Infect Dis. 2003 Oct 15;188(8):1213-30. doi: 10.1086/378356. Epub 2003 Oct 3. J Infect Dis. 2003. PMID: 14551893 Clinical Trial. - Protection against Japanese encephalitis by inactivated vaccines.
Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, et al. Hoke CH, et al. N Engl J Med. 1988 Sep 8;319(10):608-14. doi: 10.1056/NEJM198809083191004. N Engl J Med. 1988. PMID: 2842677 Clinical Trial. - Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature.
Chung CC, Lee SS, Chen YS, Tsai HC, Wann SR, Kao CH, Liu YC. Chung CC, et al. Infection. 2007 Feb;35(1):30-2. doi: 10.1007/s15010-007-6038-7. Infection. 2007. PMID: 17297587 Review. - Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains.
Kurane I, Takasaki T. Kurane I, et al. Vaccine. 2000 May 26;18 Suppl 2:33-5. doi: 10.1016/s0264-410x(00)00041-4. Vaccine. 2000. PMID: 10821971 Review.
Cited by
- Safety of Japanese encephalitis vaccines.
Hu YL, Lee PI. Hu YL, et al. Hum Vaccin Immunother. 2021 Nov 2;17(11):4259-4264. doi: 10.1080/21645515.2021.1969852. Epub 2021 Oct 6. Hum Vaccin Immunother. 2021. PMID: 34613870 Free PMC article. - Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.
Hegde NR, Gore MM. Hegde NR, et al. Hum Vaccin Immunother. 2017 Jun 3;13(6):1-18. doi: 10.1080/21645515.2017.1285472. Epub 2017 Feb 22. Hum Vaccin Immunother. 2017. PMID: 28301270 Free PMC article. Review. - Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.
Fan YC, Chiu HC, Chen LK, Chang GJ, Chiou SS. Fan YC, et al. PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004167. doi: 10.1371/journal.pntd.0004167. eCollection 2015 Oct. PLoS Negl Trop Dis. 2015. PMID: 26495991 Free PMC article. - Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
Yun KW, Lee HJ, Kang JH, Eun BW, Kim YJ, Kim KH, Kim NH, Hong YJ, Kim DH, Kim HM, Cha SH. Yun KW, et al. BMC Infect Dis. 2015 Jan 8;15:7. doi: 10.1186/s12879-014-0744-4. BMC Infect Dis. 2015. PMID: 25567119 Free PMC article. Clinical Trial. - Japanese encephalitis: the virus and vaccines.
Yun SI, Lee YM. Yun SI, et al. Hum Vaccin Immunother. 2014;10(2):263-79. doi: 10.4161/hv.26902. Epub 2013 Oct 25. Hum Vaccin Immunother. 2014. PMID: 24161909 Free PMC article. Review.